Unknown

Dataset Information

0

In vitro and in vivo immunomodulatory properties of octyl-?-D-galactofuranoside during Leishmania donovani infection.


ABSTRACT:

Background

The chemotherapeutic arsenal available to treat visceral leishmaniasis is currently limited, in view of many drawbacks such as high cost, toxicity or emerging resistance. New therapeutic strategies are particularly needed to improve the management and the outcome in immunosuppressed patients. The combination of an immunomodulatory drug to a conventional anti-Leishmania treatment is an emerging concept to reverse the immune bias from Th2 to Th1 response to boost healing and prevent relapses.

Methods

Here, immunostimulating and leishmanicidal properties of octyl-?-D-galactofuranose (Galf) were assessed in human monocyte-derived macrophages (HM) and in a murine model, after challenge with Leishmania donovani promastigotes. We recorded parasite loads and expression of various cytokines and immune effectors in HM and mouse organs (liver, spleen, bone marrow), following treatment with free (Galf) and liposomal (L-Galf) formulations.

Results

Both treatments significantly reduced parasite proliferation in HM, as well as liver parasite burden in vivo (Galf, P?ConclusionsOverall, these results suggest that Galf could be tested as an adjuvant in combination with current anti-parasitic drugs, to restore an efficient immune response against infection in a model of immunosuppressed mice.

SUBMITTER: Guegan H 

PROVIDER: S-EPMC6929453 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vitro and in vivo immunomodulatory properties of octyl-β-D-galactofuranoside during Leishmania donovani infection.

Guegan Hélène H   Ory Kevin K   Belaz Sorya S   Jan Aurélien A   Dion Sarah S   Legentil Laurent L   Manuel Christelle C   Lemiègre Loïc L   Vives Thomas T   Ferrières Vincent V   Gangneux Jean-Pierre JP   Robert-Gangneux Florence F  

Parasites & vectors 20191223 1


<h4>Background</h4>The chemotherapeutic arsenal available to treat visceral leishmaniasis is currently limited, in view of many drawbacks such as high cost, toxicity or emerging resistance. New therapeutic strategies are particularly needed to improve the management and the outcome in immunosuppressed patients. The combination of an immunomodulatory drug to a conventional anti-Leishmania treatment is an emerging concept to reverse the immune bias from Th2 to Th1 response to boost healing and pre  ...[more]

Similar Datasets

| S-EPMC6529017 | biostudies-literature
| S-EPMC2923181 | biostudies-literature
| S-EPMC4339582 | biostudies-literature
| S-EPMC8232742 | biostudies-literature
| S-EPMC5442457 | biostudies-literature
| S-EPMC7943006 | biostudies-literature
| S-EPMC5665970 | biostudies-literature
| S-EPMC8308600 | biostudies-literature
| S-EPMC9394181 | biostudies-literature
| S-EPMC7221892 | biostudies-literature